Controversies in the Adjuvant Therapy of Endometrial Cancer
Author(s) -
ShengMou Hsiao,
LinHung Wei
Publication year - 2011
Publication title -
isrn obstetrics and gynecology
Language(s) - English
Resource type - Journals
eISSN - 2090-4444
pISSN - 2090-4436
DOI - 10.5402/2011/724649
Subject(s) - endometrial cancer , medicine , adjuvant therapy , hysterectomy , serous fluid , randomized controlled trial , cancer , malignancy , adjuvant , oncology , gynecology , clinical trial , surgery
Endometrial cancer is the most common malignancy of the female genital tract. Surgical treatment includes hysterectomy, bilateral salpingo-oophorectomy, and an appropriate staging procedure. Relapse of endometrial cancer may occur in patients with high risk factors, such as old age, grade 3 cancer, deep myometrial invasion, and papillary serous and clear cell types. In recent years, several randomized trials reported the results of adjuvant therapy for patients with high risk factors. Nonetheless, some controversies still exist. This paper presents and discusses the results of important randomized trials of adjuvant therapy for endometrial cancer with risk factors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom